Fig. 3
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12916-015-0455-8/MediaObjects/12916_2015_455_Fig3_HTML.gif)
Incidence of global immune-related adverse events (irAEs) with anti-CTLA-4, all-grade (a) and severe grade (b). For ipilimumab treatment, different dosages were used: 3 mg/kg, 10 mg/kg, and 15 mg/kg. Only one study [31] reported global irAEs with tremelimumab treatment, at 15 mg/kg dosage. IrAEs associated with anti-CTAL-4 antibodies (c)